Grifols, S.A.

GRFS Healthcare Drug Manufacturers General

Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024. In the quarter to June 2026, revenue grew 5.76%, EPS grew 466.9%, free cash flow grew 300.5% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

7.64 0.10 +1.33%
Market cap
$2.0B
P/E
8.5×
Fwd P/E
—
Dividend yield
1.24%
F-score
5/9
Altman Z
1.38
Beneish M
−2.59
Dividend safety
54/100
Dec '25 Dec '24 Dec '23 Dec '22 Jan '22 Dec '21 Jan '21 Dec '20 Jan '20 Dec '19
Piotroski F-Score
5 8 7 3 — 4 — 4 — 5
P/E ratio
10.35 20.88 55.25 24.97 20.49 19.76 18.13 17.64 20.60 20.33
Altman Z-Score
1.38 1.22 1.28 1.10 — 1.13 — 1.89 — 2.19
P/S ratio
0.75 0.75 0.00 0.24 0.40 0.39 2.10 2.04 2.96 2.92
Altman Z″-Score (non-manufacturers)
2.86 2.82 2.83 2.44 — 2.28 — 2.99 — 3.76
P/FCF ratio
9.85 18.29 0.00 272.22 5.94 5.73 21.23 20.66 39.87 39.35
Beneish M-Score
(2.59) (2.49) (2.51) (2.08) — (2.53) — (2.43) — (2.32)
P/Operating CF
13.70 16.66 0.00 (59.09) 9.85 9.50 39.11 38.06 61.90 61.09
Dividend Safety Score
54 — — — — — — — — —
P/B ratio
0.74 0.94 0.00 0.34 0.43 0.42 2.06 2.00 3.01 2.97
Price to Tangible BV
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Sales
1.91 2.10 1.34 1.27 1.74 1.72 3.37 3.31 3.91 3.87
EV/EBITDA
8.51 10.44 7.94 7.98 9.32 9.24 13.62 13.39 14.81 14.66
EV/Operating CF
13.76 23.54 90.08 17.00 10.20 10.12 15.97 15.70 22.94 22.71
EV/FCF
25.24 51.23 (59.21) 1,462.80 25.54 25.33 34.01 33.44 52.66 52.13
Quick Ratio
0.80 0.93 0.60 0.65 0.67 0.91 0.33 0.78 0.81 2.14
Current Ratio
2.51 2.66 2.79 2.38 2.38 1.59 1.59 2.37 2.37 3.92
Net Debt/EBITDA
5.19 5.49 8.37 8.38 8.41 7.88 9.45 4.88 4.88 3.30
Debt/Assets
48.92% 47.50% 51.57% 49.95% 45.01% 53.07% 48.28% 46.00% 45.25% 46.38%
Debt/Equity
1.27 1.18 1.39 1.27 1.59 1.40 1.69 1.05 1.35 1.05
Asset Turnover
0.37 0.34 0.31 0.28 0.00 0.29 0.00 0.35 0.00 0.36
Operating CF/Net income
2.60 5.75 3.51 (0.05) 0.00 3.16 3.22 1.80 1.81 0.91
Capex/Depreciation
(0.93) (0.79) (0.66) (0.91) 0.00 (0.19) 0.00 (1.13) 0.00 (1.35)
Interest Coverage
1.99 1.67 1.34 1.62 40.35 2.14 94.17 3.99 243.75 3.30
ROE
5.08% 1.89% 0.73% 2.50% 0.00% 2.73% 0.00% 9.21% 0.00% 10.60%
ROA
2.00% 0.73% 0.28% 0.97% 0.00% 1.11% 0.00% 4.05% 0.00% 4.36%
ROIC
4.74% 4.24% 2.72% 2.70% 0.00% 2.51% 0.00% 4.73% 0.00% 6.10%
Return on Tangible Assets
6.51% 2.27% 0.80% 3.49% 3.03% 4.12% 3.51% 14.89% 12.81% 10.16%
Average Days of Receivables
36.48 39.63 39.87 41.04 45.44 36.05 36.63 31.14 34.45 32.38
Research and Development Expense of Revenue
5.66% 5.32% 6.00% 5.96% 5.23% 7.19% 6.08% 5.51% 4.89% 5.41%
Selling, General and Administrative Expense of Revenue
15.72% 17.40% 20.73% 19.63% 18.09% 21.52% 19.40% 18.46% 16.76% 18.49%
Intangible Assets out of Total Assets
0.49 0.48 0.45 0.46 0.46 0.41 0.41 0.45 0.45 0.45
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Graham Net Nets
(1.25) (1.39) 0.00 (4.06) (2.15) (2.23) (0.51) (0.53) (0.23) (0.23)
Graham Number
16.03 0.00 9.83 14.16 11.72 18.58 16.72 14.72 0.00 0.00
Earnings Yield
9.66% 4.79% 1.81% 4.00% 4.88% 5.06% 5.52% 5.67% 4.86% 4.92%
Free Cash Flow Yield
10.15% 5.47% 0.00% 0.37% 16.83% 17.45% 4.71% 4.84% 2.51% 2.54%
Revenue per Share
12.51 11.48 10.50 9.40 26.91 8.56 23.75 8.90 23.19 8.34
Operating CF per Share
1.74 1.44 0.33 (0.02) 0.00 1.04 2.93 1.85 4.86 0.93
Capex per Share
(0.70) (0.55) (0.46) (0.58) 0.00 (0.12) 0.00 (0.60) 0.00 (0.67)
Free Cash Flow per Share
1.04 0.88 (0.13) (0.59) 0.00 0.92 2.93 1.25 4.86 0.26
Cash per Share
1.43 1.95 1.07 0.92 2.43 4.66 3.15 0.98 2.52 4.04
Shareholders Equity per Share
12.64 13.70 12.69 13.11 27.20 12.70 26.59 11.20 22.18 11.19
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
12.64 13.70 12.69 13.11 27.20 12.70 26.59 11.20 22.18 11.19
Free Cash Flow
710.52 599.81 (88.43) (403.68) 0.00 626.92 750.62 854.50 1,258.43 178.46
Working Capital
3,456.43 3,864.61 4,476.72 2,842.34 3,065.91 2,408.75 2,513.58 2,090.20 2,056.18 4,475.10
Capital Expenditures
(474.06) (376.42) (313.86) (392.23) (427.27) (79.36) (388.89) (413.84) (407.87) (458.75)
Net Current Asset Value
(7,959.40) (7,651.18) (7,594.13) (8,874.31) (9,698.86) (7,579.48) (7,987.65) (6,156.73) (6,037.08) (3,734.82)
EV/EBIT
11.59 12.65 12.87 10.52 10.55 10.46 16.20 15.93 17.19 17.02
Capex to Sales
0.06 0.05 0.04 0.06 0.00 0.01 0.00 0.07 0.00 0.08
Price to Operating Income
4.52 4.51 0.00 1.96 2.45 2.37 10.11 9.84 13.02 12.85
Other line items
Depreciation/Fixed assets
0.14 0.13 0.14 0.12 0.10 0.14 0.11 0.14 0.11 0.14
Cash ROIC
3.47% 2.77% (0.41%) (1.93%) 0.00% 2.62% 3.92% 5.22% 8.89% 0.96%
Accounts Receivable Turnover
10.03 9.60 9.53 9.87 0.00 10.64 0.00 11.88 0.00 12.23
Accounts Payable Turnover
5.63 5.30 5.37 5.33 0.00 4.91 0.00 5.26 0.00 4.70
Inventory Turnover
1.39 1.26 1.25 1.34 0.00 1.42 0.00 1.44 0.00 1.25
Average Days of Payables
65.80 70.42 72.43 69.71 67.38 77.29 73.61 71.18 68.49 77.02
Days of Inventory on Hand
257.89 294.13 308.16 304.90 294.67 277.62 264.36 236.91 227.78 310.08
Average Receivables
849.05 813.30 748.86 647.45 717.22 548.45 565.77 513.50 536.44 466.81
Average Payables
936.89 901.16 825.59 757.65 787.99 715.69 731.89 669.47 664.06 657.65
Average Inventory
3,790.74 3,798.18 3,558.46 3,023.00 3,155.27 2,480.12 2,538.05 2,455.45 2,436.57 2,462.95
Average Assets
22,732.39 23,184.13 22,946.93 22,721.88 23,685.16 20,101.97 20,645.18 17,428.05 17,285.32 16,071.56
Average Common Equity
8,957.85 8,971.14 8,769.75 8,783.86 7,811.38 8,166.59 7,248.04 7,671.79 6,703.29 6,606.98

Fold the line items

Columns are period end dates